New readers and writers of RNA modifications unique to leukemia stem cells

Takeshi Fujino; Omar Abdel-Wahab

doi:10.1016/j.stem.2022.12.011

New readers and writers of RNA modifications unique to leukemia stem cells

Cell Stem Cell. 2023 Jan 5;30(1):3-4. doi: 10.1016/j.stem.2022.12.011.

Authors

Takeshi Fujino¹, Omar Abdel-Wahab²

Affiliations

¹ Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: abdelwao@mskcc.org.

PMID: 36608677
DOI: 10.1016/j.stem.2022.12.011

Abstract

Chemical modifications of RNA are regulated by a series of readers, writers, and erasers that dictate gene expression. Two new studies in Cell Stem Cell¹^,²identify roles for the N⁶-methyladenosine (m⁶A) methyltransferase METTL16 and the m⁶A reader IGF2BP2 in leukemia-initiating cells, illuminating exciting new therapeutic targets for leukemia.

Publication types

Comment

MeSH terms

Humans
Leukemia* / genetics
Methylation
Methyltransferases / genetics
RNA* / genetics
RNA* / metabolism
RNA-Binding Proteins / genetics
RNA-Binding Proteins / metabolism
Stem Cells / metabolism

Substances

RNA
Methyltransferases
IGF2BP2 protein, human
RNA-Binding Proteins
METTL16 protein, human